Last reviewed · How we verify
Bipolar Disorder — Treatment Landscape & Competitive Intelligence
Psychiatry
5 marketed
0 Phase 3
0 Phase 2
Live · 30-min refresh
Marketed treatment landscape
| Drug | Generic | Sponsor | Class | Target | Line of therapy | First approval |
|---|---|---|---|---|---|---|
| Lithium Citrate | LITHIUM CITRATE | Hikma | lithium | Glycogen synthase kinase-3 | 1980-01-01 | |
| Lithobid | lithium carbonate | Generic (multiple manufacturers) | Mood stabilizer | Inositol-1(or 4)-monophosphatase 1, Glycogen synthase kinase-3 | 1970-04-06 | |
| Seroquel | quetiapine | AstraZeneca | Aldehyde oxidase, 5-hydroxytryptamine receptor 1E, 5-hydroxytryptamine receptor 5A | |||
| Seroquel | Seroquel | University of Pittsburgh | Aldehyde oxidase, 5-hydroxytryptamine receptor 1E, 5-hydroxytryptamine receptor 5A | |||
| Quetiapin | Quetiapin | Sykehuset Innlandet HF | Aldehyde oxidase, 5-hydroxytryptamine receptor 1E, 5-hydroxytryptamine receptor 5A |
Phase 3 pipeline
Phase 2 pipeline
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Sponsor landscape
- · 2 drugs in Bipolar Disorder
- AstraZeneca · 1 drug in Bipolar Disorder
- Generic (multiple manufacturers) · 1 drug in Bipolar Disorder
- Hikma · 1 drug in Bipolar Disorder
- Sykehuset Innlandet HF · 1 drug in Bipolar Disorder
- University of Pittsburgh · 1 drug in Bipolar Disorder
Subscribe to ongoing alerts
Every new regulatory action, PDUFA date, or trial completion in Bipolar Disorder:
- Bipolar Disorder treatment updates — RSS
- Bipolar Disorder treatment updates — Atom
- Bipolar Disorder treatment updates — JSON
Cite this brief
Drug Landscape (2026). Bipolar Disorder — Treatment Landscape & Competitive Intelligence Brief. https://druglandscape.com/ci/disease/bipolar-disorder. Accessed 2026-05-13.
Related
- Bipolar Disorder full disease profile — treatment pathway, diagnostics, guidelines
- Psychiatry area landing
- Browse all CI briefs
- Build a custom feed